K2M Group Holdings, Inc. (NASDAQ:KTWO)‘s stock had its “buy” rating reiterated by stock analysts at Oppenheimer Holdings, Inc. in a research note issued to investors on Thursday.

Several other research firms also recently issued reports on KTWO. Needham & Company LLC restated a “buy” rating and set a $29.00 target price on shares of K2M Group Holdings in a research report on Tuesday, March 7th. Zacks Investment Research upgraded K2M Group Holdings from a “sell” rating to a “hold” rating in a research report on Thursday, March 23rd. JMP Securities restated an “outperform” rating and set a $27.00 target price on shares of K2M Group Holdings in a research report on Wednesday, April 12th. TheStreet upgraded K2M Group Holdings from a “d+” rating to a “c” rating in a research report on Monday, May 8th. Finally, Barclays PLC increased their target price on K2M Group Holdings from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, April 24th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $25.13.

Analyst Recommendations for K2M Group Holdings (NASDAQ:KTWO)

Shares of K2M Group Holdings (NASDAQ:KTWO) traded up 1.74% during trading on Thursday, reaching $23.92. The company’s stock had a trading volume of 2,519,027 shares. K2M Group Holdings has a 52-week low of $14.49 and a 52-week high of $23.93. The stock’s market cap is $1.02 billion. The stock has a 50-day moving average of $22.48 and a 200-day moving average of $21.08.

K2M Group Holdings (NASDAQ:KTWO) last announced its quarterly earnings data on Tuesday, May 2nd. The medical device company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.02. K2M Group Holdings had a negative net margin of 17.48% and a negative return on equity of 16.02%. The firm had revenue of $61.89 million for the quarter, compared to the consensus estimate of $60.10 million. Analysts predict that K2M Group Holdings will post ($0.80) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “K2M Group Holdings’ (KTWO) Buy Rating Reiterated at Oppenheimer Holdings, Inc.” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/06/24/k2m-group-holdings-ktwo-buy-rating-reiterated-at-oppenheimer-holdings-inc.html.

In other K2M Group Holdings news, CFO Gregory S. Cole sold 42,947 shares of the stock in a transaction on Friday, June 16th. The stock was sold at an average price of $22.80, for a total transaction of $979,191.60. Following the sale, the chief financial officer now owns 87,425 shares in the company, valued at $1,993,290. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John Philip Md Kostuik sold 50,000 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $22.70, for a total value of $1,135,000.00. Following the sale, the insider now owns 199,107 shares in the company, valued at approximately $4,519,728.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 94,849 shares of company stock worth $2,155,454. Company insiders own 5.80% of the company’s stock.

Several large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. increased its stake in shares of K2M Group Holdings by 11.7% in the first quarter. Goldman Sachs Group Inc. now owns 116,037 shares of the medical device company’s stock worth $2,380,000 after buying an additional 12,194 shares during the period. Point72 Asset Management L.P. increased its stake in shares of K2M Group Holdings by 114.0% in the first quarter. Point72 Asset Management L.P. now owns 555,500 shares of the medical device company’s stock worth $11,393,000 after buying an additional 295,900 shares during the period. Driehaus Capital Management LLC acquired a new stake in shares of K2M Group Holdings during the first quarter worth about $4,753,000. Credit Suisse AG increased its stake in shares of K2M Group Holdings by 9.8% in the first quarter. Credit Suisse AG now owns 212,672 shares of the medical device company’s stock worth $4,360,000 after buying an additional 18,931 shares during the period. Finally, Tudor Investment Corp ET AL increased its stake in shares of K2M Group Holdings by 50.3% in the first quarter. Tudor Investment Corp ET AL now owns 31,420 shares of the medical device company’s stock worth $644,000 after buying an additional 10,519 shares during the period. Institutional investors own 98.82% of the company’s stock.

K2M Group Holdings Company Profile

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.